Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: J Allergy Clin Immunol. 2017 Mar 9;140(2):612–614.e5. doi: 10.1016/j.jaci.2017.02.016

Table I.

Clinical features of the 56 patients with cartilage-hair hypoplasia.

Clinical feature Proportion of patients Comments

Clinical humoral immunodeficiency 26/56 (46%) Defined as otitis media and/or rhinosinusitis requiring surgical interventions, sepsis, pneumonia and/or bronchiectasis.

Clinical combined immunodeficiency 15/56 (27%) Defined as a history of severe warts, recurrent and/or severe herpes virus infections, malignancy and/or autoimmunity, with clinical signs of humoral immunodeficiency.

Pneumonia 11/56 (20%)
 recurrent  4/11 (36%)
 hospitalization  5/11 (45%)

Bronchiectasis 10/34 (29%) Diagnosed on lung high-resolution computed tomography.

Sinusitis 33/56 (59%)
 sinus surgery  21/33 (64%)

Otitis media 41/56 (73%)
 tympanostomy  16/41 (39%)

Sepsis 3/56 (5%)

History of warts 19/56 (34%) Out of two patients with severe warts, one underwent partial amputation of the toe with warts for suspected malignancy and another had protracted history of wide-spread warts.
 warts at the time of visit  14/19 (74%)
 severe warts  2/19 (11%)

Varicella 42/56 (75%) History of varicella or positive serology for varicella-zoster virus.
 hospitalization  5/42 (12%)

Boils 3/56 (5%)
 recurrent  2/3 (67%)

Mucocutaneous herpes simplex virus infection 2/56 (4%) One patient had required continuous acyclovir prophylaxis for 15 yrs for recurrent skin herpes simplex virus infections.

Allergy 23/56 (41%) History of allergic rhinoconjunctivitis.

Malignancy 9/56 (16%) Other malignancies included uterus carcinoma in one patient and vocal cord carcinoma in another.
 lymphoma  2/9 (22%)
 basal cell carcinoma only  5/9 (56%)
 other  2/9 (22%)

Autoimmunity 1/56 (2%) Juvenile idiopathic arthritis.

Prophylactic antibiotics 7/56 (13%) Sulfamethoxazole/trimethoprim or azithromycin, commenced for recurrent infections or lymphopenia.

Immunoglobulin substitution 7/56 (13%) In four patients treatment was still ongoing at the time of the study.